Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences Inc. received an initial ownership report on Form 3 from RA Capital–affiliated entities as ten percent owners. The filing lists indirect holdings of 28,569, 109,661, and 11,897,896 shares of Common Stock held through investment vehicles managed by RA Capital Management, L.P.
The report also shows 8,178,412 Pre-Funded Warrants, each exercisable into one share of Common Stock at an exercise price of $0.001 per share. These warrants are exercisable immediately but subject to a 9.99% beneficial ownership limit that caps how many shares the Fund may hold after exercise.
RA Capital Management and affiliates report an updated stake in Solid Biosciences Inc., now beneficially owning 12,036,126 shares of common stock, or 11.9% of the company. Most of this is held through RA Capital Healthcare Fund, which directly owns 11,897,896 shares.
The position also includes pre-funded warrants exercisable for up to 8,178,412 additional shares, but a Beneficial Ownership Blocker prevents exercises that would lift the Fund’s holdings above 9.99% of Solid’s outstanding common stock. RA Capital serves as investment adviser to all reporting vehicles, while Kolchinsky and Shah are managers of RA Capital.
On June 18, 2026, the Fund bought 338,100 shares in open-market trades at prices between $8.25 and $8.35, with a weighted-average of $8.30 per share. On June 22, 2026, it purchased an additional 2,358,048 shares at $8.20 per share in an at-the-market offering by Solid Biosciences, all funded from the Fund’s working capital. Ownership percentages are calculated using 98,449,606 shares outstanding as of May 8, 2026, plus the 2,358,048 new ATM shares issued to the Fund.
Solid Biosciences Inc. reported that director Nagendran Sukumar received a grant of stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and expire on June 10, 2036.
The grant vests in full on the earlier of the one-year anniversary of June 10, 2026 or immediately before the company’s next annual stockholder meeting after that date. Any remaining unvested portion will also vest automatically upon specified change in control events, aligning the director’s compensation with company performance and potential strategic transactions.
Solid Biosciences director Ian F. Smith received a grant of stock options covering 77,500 shares of common stock. The Director Stock Option has an exercise price of $6.61 per share and, after this grant, Smith holds options on 77,500 shares directly.
The option was granted on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders after the grant date. Any remaining unvested portion will also vest automatically upon specified change in control events. The option expires on June 10, 2036.
Solid Biosciences Inc. director Ilan Ganot received a new stock option grant. The Form 4 reports an award of 77,500 Director Stock Options, each exercisable for one share of common stock at an exercise price of $6.61 per share.
The option was granted on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholders’ meeting after the grant. Any remaining unvested portion will also vest automatically upon specified change in control events. Following this award, Ganot directly holds options for 77,500 underlying shares.
Solid Biosciences Inc. reported a Form 4 insider transaction showing a director stock option grant linked to board service. Options to purchase 77,500 shares of common stock at an exercise price of $6.61 per share were awarded to Board member Adam Stone as compensation.
The option vests in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the next annual stockholder meeting, with full acceleration upon specified change in control events. Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund Ltd. report an indirect pecuniary interest through a management fee offset and each disclaims beneficial ownership beyond that indirect interest.
Solid Biosciences Inc. director Georgia Keresty received a new stock option grant. On June 10, 2026, she was awarded options for 77,500 shares of common stock at an exercise price of $6.61 per share. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, and will also fully vest upon specified change in control events. Following this grant, her reported derivative holdings from this award total 77,500 options, expiring on June 10, 2036.
Solid Biosciences Inc. director Martin I. Freed received a grant of stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and were awarded at no upfront cost as a compensation grant.
The option vests in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the company’s next annual meeting of stockholders after that date, and will fully vest on specified change in control events. Following this grant, Freed holds 77,500 stock options directly.
Solid Biosciences Inc. director Clare Kahn received a grant of stock options to acquire 77,500 shares of common stock. The options have an exercise price of $6.61 per share and were awarded at no cost as equity compensation.
The option grant was made on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual stockholder meeting after the grant date. Any unvested portion will also vest automatically upon specified change in control events.
Solid Biosciences Inc. director Lynne Marie Sullivan received a grant of director stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and expire on June 10, 2036.
The grant was made on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders after the grant. Any unvested portion will vest automatically upon specified change in control events. This is a compensation-related award rather than an open-market purchase.